These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18985968)

  • 1. Distribution of certain drug products by registered blood establishments and comprehensive hemophilia diagnostic treatment centers that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements and administrative procedures. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Oct; 73(197):59496-501. PubMed ID: 18985968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Dec; 64(232):67720-63. PubMed ID: 11010665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
    Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prescription Drug Marketing Act of 1987.
    Greenberg RB
    Am J Hosp Pharm; 1988 Oct; 45(10):2118-26. PubMed ID: 3228083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare program; rural health clinics: amendments to participation requirements and payment provisions; and establishment of a quality assessment and performance improvement program; suspension of effectiveness. Interim final rule with comment period; partial suspension of effectiveness.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2006 Sep; 71(184):55341-7. PubMed ID: 17017468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare program: Medicare Advantage and Prescription Drug Benefit programs: final marketing provisions. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Sep; 73(182):54207-23. PubMed ID: 18985950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare Program; revisions to the Medicare Advantage and Prescription Drug Benefit programs. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Sep; 73(182):54225-54. PubMed ID: 18985953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality mammography standards--FDA. Final rule.
    Fed Regist; 1997 Oct; 62(208):55852-994. PubMed ID: 10177306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare program; revised payment system policies for services furnished in ambulatory surgical centers (ASCs) beginning in CY 2008. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Aug; 72(148):42469-626. PubMed ID: 17682288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.